Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
Beta Particles
Breast Neoplasms
/ metabolism
Cell Line, Tumor
ErbB Receptors
/ metabolism
Female
Gold
/ chemistry
Humans
Immunoconjugates
/ chemistry
Lutetium
/ chemistry
Metal Nanoparticles
/ chemistry
Nanomedicine
/ methods
Panitumumab
/ chemistry
Polyethylene Glycols
/ chemistry
Radioimmunotherapy
/ methods
Radioisotopes
/ chemistry
Radiopharmaceuticals
/ chemistry
Receptor, ErbB-2
/ metabolism
Trastuzumab
/ chemistry
EGFR
HER2
breast cancer
gold nanoparticles
panitumumab
trastuzumab, lutetium-177
Journal
Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791
Informations de publication
Date de publication:
06 04 2020
06 04 2020
Historique:
pubmed:
6
2
2020
medline:
29
5
2021
entrez:
6
2
2020
Statut:
ppublish
Résumé
Resistance to HER2-targeted therapies in breast cancer (BC) is associated in some cases with an increased expression of epidermal growth factor receptors (EGFR). We describe a dual-receptor-targeted (DRT) radiation nanomedicine for local intratumoral (i.t.) treatment of BC composed of 15 nm sized gold nanoparticles (AuNPs) modified with trastuzumab (TmAb) to target HER2 and panitumumab (PmAb) to target EGFR. The AuNPs were modified with poly(ethylene glycol) (PEG
Identifiants
pubmed: 32022567
doi: 10.1021/acs.molpharmaceut.9b01259
doi:
Substances chimiques
Immunoconjugates
0
Radioisotopes
0
Radiopharmaceuticals
0
Polyethylene Glycols
3WJQ0SDW1A
Lutetium
5H0DOZ21UJ
Panitumumab
6A901E312A
Gold
7440-57-5
Lutetium-177
BRH40Y9V1Q
EGFR protein, human
EC 2.7.10.1
ERBB2 protein, human
EC 2.7.10.1
ErbB Receptors
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Trastuzumab
P188ANX8CK
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM